Distalmotion, an Epalinges, Switzerland-based medical device company, raised $150M in funding.
The round was led by Revival Healthcare Capital.
The company intends to use the funds to enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe.
Led by CEO Michael Friedrich, Distalmotion is a medical device company which works to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to minimally invasive care. To do so, the company has developed a surgical robot called Dexter. Designed, developed and manufactured in Switzerland, Dexter is in day-to-day clinical use in Europe, treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, urology.
FinSMEs
24/04/2023